Taysha Gene Therapies: Funding, Investors & Team (Sep 2026)
Taysha Gene Therapies is dedicated to eliminating serious and life-threatening genetic diseases in the central nervous system. Our main goal is to develop treatments that can provide a cure, allowing us to quickly transition from laboratory research to patient treatment. By leveraging the expertise of our team in gene therapy and collaborating with the prestigious UT Southwestern Gene Therapy Program, we have created a robust pipeline of AAV gene therapy options that target rare and common diseases.
Taysha Gene Therapies has raised $710M across 7 funding rounds on record, the most recent an undisclosed round of $200M announced in Jun 2026.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Taysha Gene Therapies Company Profile and Key Stats
Latest funding round on record: Jun 2026.
Taysha Gene Therapies Funding Rounds
Taysha Gene Therapies raised $95.0M in an undisclosed round announced in Aug 2020.
1 years later, a Post-IPO Debt of $100M was announced in Aug 2021.
1.2 years later, a Post-IPO Equity of $50.0M was announced in Oct 2022.
10 months later, an undisclosed round of $150M was announced in Aug 2023.
4 months later, an undisclosed round of $40.0M was announced in Dec 2023.
6 months later, an undisclosed round of $75.0M was announced in Jun 2024.
2 years later, an undisclosed round of $200M was announced in Jun 2026.
Taysha Gene Therapies Founders and Leadership Team
Contact details for the Taysha Gene Therapies team: 2 of 4 have an email address on file.
Start 14-day free trial →Taysha Gene Therapies Funding Compared to Other Biotechnology Startups
Taysha Gene Therapies' latest round of $200M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Taysha Gene Therapies in Biotechnology and Dallas
Companies Similar to Taysha Gene Therapies
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Paterna BioSciences, Inc. is a pioneering biotechnology company dedicated to solving the significant…
Legendary Bio's solidarity is a determined spotlight on introducing another period of quality guideline.
Cataract surgery is the single most common procedure performed in the United States annually. Despite…
InSitu Biologics is a developer of a drug delivery platform designed to focus on development of new and…
Remedium Bio is a gene therapy company in the Boston area that is dedicated to developing cures for severe…
Taysha Gene Therapies Funding FAQs
What does Taysha Gene Therapies do?
Taysha Gene Therapies is dedicated to eliminating serious and life-threatening genetic diseases in the central nervous system. Our main goal is to develop treatments that can provide a cure, allowing us to quickly transition from laboratory research to patient treatment. By leveraging the expertise of our team in gene therapy and collaborating with the prestigious UT Southwestern Gene Therapy Program, we have created a robust pipeline of AAV gene therapy options that target rare and common diseases.
How much funding has Taysha Gene Therapies raised?
Taysha Gene Therapies has raised $710M across 7 rounds on record. The most recent is an undisclosed round of $200M announced in Jun 2026.
When did Taysha Gene Therapies last raise funding?
Taysha Gene Therapies' most recent funding round on record is an undisclosed round of $200M, announced in Jun 2026.
Who founded Taysha Gene Therapies?
FundedIQ lists Sean Nolan (Founder) at Taysha Gene Therapies.
Who is the CEO of Taysha Gene Therapies?
R.A. Session II is listed as CEO at Taysha Gene Therapies.
Where is Taysha Gene Therapies headquartered?
Taysha Gene Therapies is based in Dallas, Texas, United States.
How many employees does Taysha Gene Therapies have?
Taysha Gene Therapies is in the 101-250 employee band.
How does Taysha Gene Therapies' funding compare to other Biotechnology startups?
Taysha Gene Therapies' latest round of $200M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Taysha Gene Therapies Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Taysha Gene Therapies is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.